What is Xeris Biopharma Holdings 6-1 Month Momentum %?
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-12), Xeris Biopharma Holdings's 6-1 Month Momentum % is 17.51%.
The industry rank for Xeris Biopharma Holdings's 6-1 Month Momentum % or its related term are showing as below:
XERS's 6-1 Month Momentum % is ranked better than 61.99% of 1531
companies
in the Biotechnology industry
Industry Median: 2.29
vs XERS: 17.51
Competitive Comparison of Xeris Biopharma Holdings's 6-1 Month Momentum %
For the Biotechnology subindustry, Xeris Biopharma Holdings's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Xeris Biopharma Holdings 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your